Skip to content

A Single-arm, Single-center Study of the Efficacy and Safety of Low-Concentration Sevoflurane in Patients with Attention-Deficit/Hyperactivity Disorder

A Single-arm, Single-center Study of the Efficacy and Safety of Low-Concentration Sevoflurane in Patients with Attention-Deficit/Hyperactivity Disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126392
Enrollment
Unknown
Registered
2026-06-08
Start date
2026-06-08
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

Sponsors

Guangzhou Medical University Affiliated Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). 2. Aged between 3 and 18 years (inclusive), with no gender restriction. 3. The subject is able to complete all assessments. 4. The subject's parent or legal guardian has adequate reading and comprehension skills to cooperate in completing the relevant assessment scales and follow-up visits. 5. The subject, parent, or legal guardian voluntarily participates in this study after signing written informed consent. (For children aged 8 years and older, in addition to the signed informed consent from the legal guardian, a child/adolescent version of the informed consent form (or verbal/pictorial aids) will be used to ensure the child's assent based on understanding, thereby fully protecting the subject's autonomy.)

Exclusion criteria

Exclusion criteria: 1. Presence of other psychiatric disorders besides attention-deficit/hyperactivity disorder (e.g., autism, epilepsy, schizophrenia, cerebral ischemia/hypoxia, encephalitis, history of traumatic brain injury, poisoning/intoxication, etc.). 2. Presence of serious physical illnesses or other systemic diseases (e.g., renal, hepatic, or metabolic disorders; neoplasms; infections; organic neurological diseases; endocrine or immune disorders; relevant medical history thereof). 3. Serum potassium or magnesium levels outside the normal range. 4. History of neuroleptic malignant syndrome or tardive dyskinesia. 5. Use of monoamine oxidase inhibitor antidepressants within 2 weeks prior to the study. 6. Use of central stimulants or non-stimulants within 3 months prior to the study. 7. Participation in another study within 30 days prior to the start of the current study and/or during the study period.

Design outcomes

Primary

MeasureTime frame
SNAP-IV score;

Secondary

MeasureTime frame
Conners Comprehensive Behavior Rating Scale;ADHD Rating Scale-IV;Clinical Global Impression-Severity;Clinical Global Impression-Improvement;Electroencephalogram;Functional Magnetic Resonance Imaging;

Countries

China

Contacts

Public ContactXingrong Song

Guangzhou Medical University Affiliated Women and Children's Medical Center

sxjess@126.com+86 139 2241 6303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026